Not recruiting
Psoriasis
Not recruitingInvestigational
ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
Investigational
- Disease:Psoriasis
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 4
- recruiting
- 3 961
- countries
- 28
- conditions
- 2 103
3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today
110 trials match your criteria
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:–
Countries:Germany
Germany- Participants:18–64 years · 65+ years
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:–
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
A study testing BFB759 compared to placebo to evaluate effectiveness and safety in adult patients with atopic dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:–
Countries:Germany
Germany- Participants:18–64 years · 65+ years
Not recruiting
Psoriasis
Not recruitingRegistered drug
Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis
Registered drug
- Disease:Psoriasis
- Substances:ApremilastZasocitinib
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Apremilast
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:Rocatinlimab
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Rocatinlimab
Not recruiting
Dermatitis atopic
Not recruitingRegistered drug
Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks
Registered drug
- Disease:Dermatitis atopic
- Substances:–
Countries:Germany
Germany- Participants:0–17 years
Not recruiting
Hidradenitis
Not recruitingInvestigationalNo placebo
Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa
InvestigationalNo placebo
- Disease:Hidradenitis
- Substances:Sonelokimab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Sonelokimab
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments
Investigational
- Disease:Dermatitis atopic
- Substances:Ruxolitinib
Countries:Germany
Germany- Participants:0–17 years
- Substances:Ruxolitinib
Not recruiting
Hidradenitis
Not recruitingRegistered drug
Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa
Registered drug
- Disease:Hidradenitis
- Substances:RemibrutinibSALICYLIC ACID+2
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Remibrutinib
Not recruiting
Psoriasis
Not recruitingRegistered drug
Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis
Registered drug
- Disease:Psoriasis
- Substances:Jnj-77242113Ustekinumab
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Jnj-77242113
Not recruiting
Psoriasis
Not recruitingInvestigational
Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis
Investigational
- Disease:Psoriasis
- Substances:Envudeucitinib
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Envudeucitinib